Following complete surgical resection of stage IV melanoma, evidence-based guidelines carry a strong recommendation for offering adjuvant systemic therapy to eligible patients.
This protocol applies to patients with resected stage IV melanoma — those in whom all known disease has been surgically removed. Guidelines support a strong recommendation for adjuvant treatment in this setting, based on moderate-quality evidence, with the goal of addressing residual disease risk after resection.
Adjuvant systemic therapy options include immunotherapy-based regimens and, for patients with a specific tumor mutation profile, a targeted therapy combination. The choice among options depends on individual patient and tumor factors. The full protocol details which agents apply, under what conditions, and how they are structured.